Intra-Cellular’s schizophrenia drug meets main goal in late-stage trial

(Reuters) – Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.

(Reporting by Christy Santhosh in Bengaluru; Editing by Savio D’Souza)